Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and ResistanceQUINTAS-CARDAMA, Alfonso; VERSTOVSEK, Srdan.Clinical cancer research (Print). 2013, Vol 19, Num 8, pp 1933-1940, issn 1078-0432, 8 p.Article

Mammalian target of rapamycin inhibition as therapy for hematologic malignanciesPANWALKAR, Amit; VERSTOVSEK, Srdan; GILES, Francis J et al.Cancer. 2004, Vol 100, Num 4, pp 657-666, issn 0008-543X, 10 p.Article

Efficacy of ruxolitinib for myelofibrosisSANTOS, Fabio P. S; VERSTOVSEK, Srdan.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 10, pp 1465-1473, issn 1465-6566, 9 p.Article

JAK2 inhibitors: What's the true therapeutic potential?SANTOS, Fabio P. S; VERSTOVSEK, Srdan.Blood reviews. 2011, Vol 25, Num 2, pp 53-63, issn 0268-960X, 11 p.Article

Inhibition of mammary carcinoma cell proliferation in vitro and tumor growth in vivo by bee venomORSOLIC, Nada; SVER, Lidija; VERSTOVSEK, Srdan et al.Toxicon (Oxford). 2003, Vol 41, Num 7, pp 861-870, issn 0041-0101, 10 p.Article

Aberrant Myeloid Maturation Identified by Flow Cytometry in Primary MyelofibrosisBO FENG; VERSTOVSEK, Srdan; JORGENSEN, Jeffrey L et al.American journal of clinical pathology. 2010, Vol 133, Num 2, pp 314-320, issn 0002-9173, 7 p.Article

Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?HARRISON, Claire; VERSTOVSEK, Srdan; MCMULLIN, Mary F et al.British journal of haematology. 2012, Vol 157, Num 4, pp 426-437, issn 0007-1048, 12 p.Article

Role of angiogenesis in chronic lymphocytic leukemiaLETILOVIC, Tomislav; VRHOVAC, Radovan; VERSTOVSEK, Srdan et al.Cancer. 2006, Vol 107, Num 5, pp 925-934, issn 0008-543X, 10 p.Article

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid LeukemiaLEE, Hun Ju; DAVER, Naval; KANTARJIAN, Hagop M et al.Clinical cancer research (Print). 2013, Vol 19, Num 2, pp 327-335, issn 1078-0432, 9 p.Article

Competing cell clones in myeloproliferative neoplasmAL-KALI, Aref; VERSTOVSEK, Srdan; KANTARJIAN, Hagop et al.Blood. 2010, Vol 116, Num 23, pp 5074-5075, issn 0006-4971, 2 p.Article

Experimental Therapeutics for Patients With Myeloproliferative NeoplasiasAGRAWAL, Meetu; GARG, Ravin J; CORTES, Jorge et al.Cancer. 2011, Vol 117, Num 4, pp 662-676, issn 0008-543X, 15 p.Article

Granulocytic sarcoma with massive scalp involvementQUINTAS-CARDAMA, Alfonso; HARB, Antoine J; AMIN, Hesham M et al.American journal of hematology. 2008, Vol 83, Num 4, pp 340-342, issn 0361-8609, 3 p.Article

A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophiliaKALAC, Matko; QUINTAS-CARDAMA, Alfonso; VRHOVAC, Radovan et al.Cancer. 2007, Vol 110, Num 5, pp 955-964, issn 0008-543X, 10 p.Article

New approaches in the treatment of myelofibrosisHENNESSY, Bryan T; THOMAS, Deborah A; GILES, Francis J et al.Cancer. 2005, Vol 103, Num 1, pp 32-43, issn 0008-543X, 12 p.Article

WP1066, a Novel JAK2 Inhibitor, Suppresses Proliferation and Induces Apoptosis in Erythroid Human Cells Carrying the JAK2 V617F MutationVERSTOVSEK, Srdan; MANSHOURI, Taghi; QUINTAS-CARDAMA, Alfonso et al.Clinical cancer research. 2008, Vol 14, Num 3, pp 788-796, issn 1078-0432, 9 p.Article

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. CommentaryTALLMAN, Martin S; ESTEY, Elihu; GARCIA-MANERO, Guillermo et al.Blood. 2006, Vol 107, Num 9, issn 0006-4971, 3425,3469-3473 [6 p.]Article

Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemiaVERSTOVSEK, Srdan; KANTARJIAN, Hagop; MANSHOURI, Taghi et al.Cancer. 2002, Vol 94, Num 5, pp 1517-1521, issn 0008-543XArticle

Mutation in the ATP-binding pocket of the abl kinase domain in an STI571-resistant BCR/ABL-positive cell lineRICCI, Clara; SCAPPINI, Barbara; DIVOKY, Vladimir et al.Cancer research (Baltimore). 2002, Vol 62, Num 21, pp 5995-5998, issn 0008-5472, 4 p.Article

Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluationORSOLIC, Nada; GILES, Francis J; GOURDEAU, Henriette et al.British journal of haematology. 2004, Vol 124, Num 6, pp 727-738, issn 0007-1048, 12 p.Article

Empirical examination of the neutrophil criterion (>1500 μl^-1) currently needed to declare CR in AMLESTEY, Elihu; GILES, Francis; CORTES, Jorge et al.Leukemia research. 2003, Vol 27, Num 6, pp 475-479, issn 0145-2126, 5 p.Article

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemiaALVARADO, Yesid; CORTES, Jorge; VERSTOVSEK, Srdan et al.Cancer chemotherapy and pharmacology. 2003, Vol 51, Num 1, pp 81-86, issn 0344-5704, 6 p.Article

Chronic myeloid leukemia (CML) with P190^BCR-ABL: analysis of characteristics, outcomes, and prognostic significanceVERMA, Dushyant; KANTARJIAN, Hagop M; JONES, Dan et al.Blood. 2009, Vol 114, Num 11, pp 2232-2235, issn 0006-4971, 4 p.Article

Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesvlateJABBOUR, Elias; KANTARJIAN, Hagop; O'BRIEN, Susan et al.Blood. 2006, Vol 107, Num 2, pp 480-482, issn 0006-4971, 3 p.Article

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemiaVERSTOVSEK, Srdan; LUNIN, Scott; KANTARJIAN, Hagop et al.Leukemia research. 2003, Vol 27, Num 7, pp 661-669, issn 0145-2126, 9 p.Article

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cellsSCAPPINI, Barbara; ONIDA, Francesco; KANTARJIAN, Hagop M et al.Cancer. 2002, Vol 94, Num 10, pp 2653-2662, issn 0008-543XArticle